Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Needham Thinks Collegium Pharmaceutical’s Stock is Going to Recover
November 26 2021 - 11:15AM
In a report released today, Serge Belanger from Needham maintained a Buy rating on Collegium Pharmaceutical (COLL – Research Report), with a price target of $28.00. The company's shares closed last Friday at $17.83, close to its 52-week low of $17.67. According to TipRanks.com, Belanger is a 3-star analyst with an average return of 1.8% and a 38.5% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Clarus Therapeutics Holdings, Amphastar Pharmaceuticals, and KalVista Pharmaceuticals. Currently, the analyst consensus on Collegium Pharmaceutical is a Strong Buy with an average price target of $27.00.
https://ih.advfn.com/stock-market/NASDAQ/collegium-pharmaceutical-COLL/stock-news/86665851/needham-thinks-collegium-pharmaceutical-s-stock-i
New Corporate slide show presentation at Jefferies - Nov. 18:
Select Pages 14, 15 & 22
https://ir.collegiumpharma.com/static-files/a38f74ec-ad9f-48d8-b0a2-37766a071619
FWIW -
These 40 Mass. companies made the new Deloitte Fast 500 list https://www.bizjournals.com › boston › news › 2021/11/17
The list, released Wednesday, ranks the fastest-growing technology, media, telecommunications and life sciences companies based in North America.
Collegium Pharmaceutical Inc., No. 138
Realistically, even considering the buyback & the restructuring, they need to fire their PR department. This stock has stagnated for years.
Sell the company for $85 PPS!!
Collegium Pharmaceutical price target lowered to $26 from $28 at H.C. Wainwright
H.C. Wainwright analyst Oren Livnat lowered the firm's price target on Collegium Pharmaceutical to $26 from $28 and keeps a Buy rating on the shares. The analyst sees Xtampza 20022 return to growth likely, with potential 2023 accelerations if contracts improved. Livnat added that COVID-related mix shift worsened in Q3, and that "all eyes" are now on the company's 2022 guidance and execution.
FYI - Seeking Alpha -
Risks and Conclusions
The current valuation that investors are placing on the company is likely more than just disappointment from the CRL. I think management has done a massive disservice to investors and analysts alike by not disclosing the results of the 483 during their August conference call (or sooner). Even after analysts spoke with consultants and the company, we still saw bullish notes expecting approval. With an original PDUFA date of November 25th, 2020 it remains a mystery how management could fall so short on the protocols set forth for their manufacturing processes. Now, I think we will get a lot of color on the conference call next month, and hopefully some tough questions from analysts, but it appears to me that we need to take what management says with a grain of salt until we see changes being made. I think many investors expect CEO Mark Foley to explain his timely disposition of $1m of stock two days before the company announced it had received a CRL. I was shocked by this as well, but after doing some digging it appears Mr. Foley made a similarly sized disposition on the same exact date in 2020.
We also need to take into account the risks posed by AbbVie in its recent patent infringement case filed against Revance. Analysts have largely brushed off the lawsuit's potential to matriculate into anything with substance. However, that doesn't mean that legal costs won't start to mount and eventually damage shareholder value. This is something I'll look to monitor closely.
IMHO - I wouldn't be surprised if TAKEDA bought out COLL.
Rationale:
COLL - is way too cheap! At 7 times earnings plus a $100M buyback - the stock has been going NO-WHERE. If this was a biotech - the stock would be $100+ PPS due to earnings alone.
Most importantly - Colleen Tupper - Prior to joining Collegium [in May 2021], Colleen most recently served as Chief Financial Officer, U.S. Business Unit as well as a member of the U.S. Business Unit Executive Leadership Team and the Global Finance Leadership Team at Takeda.
Prior to that role, Colleen held several roles of increasing responsibility at Shire Pharmaceuticals (acquired by Takeda in 2019) including Vice President, U.S. Commercial Finance, Vice President, Finance Integration Lead, and Vice President, Head of Finance Global Neuroscience and Ophthalmics.
https://www.collegiumpharma.com/people/colleen-tupper/
______________________________________
On April 19, 2018 Takeda made an official bid of about $66.22 (U.S.) per share, which had a value of about $60 billion (U.S.). ... Under the final bid, Shire agreed to be acquired for about $62.2 billion (U.S.), or $66.22 per share, made up of $30.33 per share in cash and 0.839 shares of Takeda stock. Jan 8, 2019
$COLL - Collegium Pharmaceuticals DCF - 20 October 2021
To all my good friends on the RVNC board - I have sold all my RVNC & will concentrate on COLL. Stay well & the best of luck.
FYI -
Our Call,18 October:
While RVNC did not disclose the specifics of the CRL, based on our conversation with a bio manufacturing expert earlier this week, we suspect that the deficiencies in the CRL had to do specifcally with observation #2 (and/or potentially #1). Our expert suggested
that observation #1 was likely fixable in a few weeks, whereas #2 had the potential to be more troublesome given its nature (i.e., using a different manufacturing process than described in the BLA).
FWIW -
Needham reiterated coverage of Revance Therapeutics with a rating of Buy and set a new price target of $25.00 from $45.00 previously
Stifel - $RVNC more optimistic saying possibly 3-6 month delay With RVNC stock set to open after $15 - find this ~ 45% drop from pre-Form-483 levels an overreaction to what could be a relatively marginal delay in light of opportunity as only differentiated, long-duration toxin in market.
Stifel - $RVNC more optimistic saying possibly 3-6 month delay With RVNC stock set to open after $15 - find this ~ 45% drop from pre-Form-483 levels an overreaction to what could be a relatively marginal delay in light of opportunity as only differentiated, long-duration toxin in market.
From your same article - how well I know -
Even more odious to FDA than manufacturing problems are repeat manufacturing problems.
Momenta Pharmaceuticals felt the effects of such repeat problems and took a financial blow when it reported in February that compliance issues at a supplier might delay approval of a high-dose version of its multiple sclerosis drug, Glatopa. After the news, Momenta’s stock price dropped 20%, and it continued to fall further.
Momenta’s development partner, Sandoz, had contracted with Pfizer for filling and finishing the final product. Pfizer, in turn, had received a warning letter in regard to a sterile injectable drug facility in McPherson, Kan. The plant is one of several with cGMP violations that Pfizer acquired when it bought Hospira in 2015.
“These repeated failures at multiple sites demonstrate that your company’s oversight and control over the manufacture of drugs is inadequate,” FDA wrote in the warning letter. That the letter was also addressed to Pfizer CEO Ian Read is noteworthy, Evercore ISI stock analyst Umer Raffat said. “When FDA addresses the letter to the senior-most person, it is trying to make a statement.”
I had to take several B/P pills after this announcement as MNTA went from a one-time high of 30 to somewhere in the high teens.
MIRACULOUSLY, I held & approximately 2 years later - J&J bought them out for $52.50.
I'm older now, not sure if I have the stamina since my nerves are now - permanently frazzled!
Updated analysts' reports - [excerpts]
Revance issues in Form 483 'must be very addressable,' says Mizuho 07:05 RVNC Mizuho analyst Vamil Divan says that while the Form 483 disclosure yesterday led to many questions and confusion from investors, Revance Therapeutics' comments last night provide comfort. Most importantly, management already responded to the questions raised in the Form 483 later that month, Divan tells investors in a research note. While management was not able to go into detail on the steps they are taking to address FDA's concerns, Divan believes the issues "must be very addressable" for the company to still expect FDA approval by the end of the year. Divan still expects approval for Daxi and keeps a Buy rating on Revance with a $36 price target.
________________________________________
Wells-Fargo
We spoke to RVNC mgmt. tonight after the company issued a PR.
A CRL has not been issued. Mgmt. commented that FDA should now have sufficient information to make an approval decision, and at this stage, does not envision a second inspection to be required.
Revance Therapeutics, Inc.
Equity Research
Price Target Basis and Risk
Price Target for RVNC: $35.00 from NC
Updated analysts' reports - [excerpts]
Revance issues in Form 483 'must be very addressable,' says Mizuho 07:05 RVNC Mizuho analyst Vamil Divan says that while the Form 483 disclosure yesterday led to many questions and confusion from investors, Revance Therapeutics' comments last night provide comfort. Most importantly, management already responded to the questions raised in the Form 483 later that month, Divan tells investors in a research note. While management was not able to go into detail on the steps they are taking to address FDA's concerns, Divan believes the issues "must be very addressable" for the company to still expect FDA approval by the end of the year. Divan still expects approval for Daxi and keeps a Buy rating on Revance with a $36 price target.
________________________________________
Wells-Fargo
We spoke to RVNC mgmt. tonight after the company issued a PR.
A CRL has not been issued. Mgmt. commented that FDA should now have sufficient information to make an approval decision, and at this stage, does not envision a second inspection to be required.
Revance Therapeutics, Inc.
Equity Research
Price Target Basis and Risk
Price Target for RVNC: $35.00 from NC
Revance issues in Form 483 'must be very addressable,' says Mizuho
[Remainder blocked from the FLY.]
Fair recovery, so far, after hours:
Open....$27.30
Block Trade Count....18
Close....$20.45
Bid
/ Ask
$22.50/23.00
Day Range....$19.51-27.44
Last Trade Size....54,869
52 Week Range....$19.51-33.83
Revance Continues to Anticipate FDA Approval of DaxibotulinumtoxinA for Injection for the Treatment of Glabellar Lines in 2021
October 12, 2021
PDF Version
- BLA for DaxibotulinumtoxinA for Injection remains under FDA review -
NASHVILLE, Tenn.--(BUSINESS WIRE)--Oct. 12, 2021-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, responds to the public disclosure of its Form 483 pursuant to a Freedom of Information Act (FOIA) request that was directed to the FDA. The Biologics License Application (BLA) for DaxibotulinumtoxinA for Injection remains under FDA review and the company continues to anticipate FDA approval of DaxibotulinumtoxinA for Injection for the treatment of glabellar lines in 2021.
Revance notes that the issuance of a Form 483 following the conclusion of an on-site inspection is not uncommon. A Form 483 lists observations made by FDA representatives during the inspection of a facility. A Form 483 does not constitute a final agency determination.
Revance provided its response to the Form 483 in July 2021 following a pre-approval inspection and is currently awaiting the FDA’s decision on its BLA for DaxibotulinumtoxinA for Injection for the treatment of glabellar lines. The company remains confident in the quality of its BLA submission and continues to anticipate FDA approval in 2021.
https://investors.revance.com/news-releases/news-release-details/revance-continues-anticipate-fda-approval-daxibotulinumtoxina
Time to buy! The FLY -
Revance likely already responded to FDA plant observations, says William Blair 15:35
RVNC
William Blair analyst Tim Lugo noted that Revance shares are trading down by more than 20% following the posting of a Form 483 by the FDA with five observations from an inspection that occurred in late June and early July. While "the public airing of concerns with the manufacturing site is leading to investor anxiety," he notes that Revance's CEO has publicly stated as recently as September that the inspection was "very typical" and that the company was still awaiting a final FDA decision. Lugo believes management's recent commentary, and "the high credibility of management," suggest the company has likely already responded to the agency and dealt with the issues raised, he tells investors. Lugo has an Outperform rating on Revance, which is down about 25% to $20.49 in late day trading.
Time to buy! The Fly -
Revance likely already responded to FDA plant observations, says William Blair 15:35
RVNC
William Blair analyst Tim Lugo noted that Revance shares are trading down by more than 20% following the posting of a Form 483 by the FDA with five observations from an inspection that occurred in late June and early July. While "the public airing of concerns with the manufacturing site is leading to investor anxiety," he notes that Revance's CEO has publicly stated as recently as September that the inspection was "very typical" and that the company was still awaiting a final FDA decision. Lugo believes management's recent commentary, and "the high credibility of management," suggest the company has likely already responded to the agency and dealt with the issues raised, he tells investors. Lugo has an Outperform rating on Revance, which is down about 25% to $20.49 in late day trading.
Basically -
"We believe the alleged patent issues asserted by Allergan in this case are not infringed upon by Revance or our supply source partner Ajinomoto or are invalid," Revance said in a statement. "We are confident in the strength of our intellectual property and have done and will vigorously defend these allegations."
The lawsuit is one of several Allergan has filed against companies threatening to cut in on its aesthetics and therapeutics applications for Botox. Revance said lawsuits are "a frequent tactic" Allergan uses to "distract their competitors."
"If anything, we believe it speaks to Allergan's concern of how impactful our differentiated product will be in the market once approved," Revance said.
https://www.bizjournals.com/sanfrancisco/news/2021/10/04/botox-allergan-revance-daxi-frown-lines-ajinomoto.html?ana=TRUEANTHEMTWT_FR&csrc=6398&taid=615bf7fd76ce460001396e2b&utm_campaign=trueAnthem%3A+Trending+Content&utm_medium=trueAnthem&utm_source=twitter
Two items:
A. Botox war: East Bay challenger sued by maker of blockbuster cosmetic toxin [**follow discussion on Biotech Values board]
Basically -
"We believe the alleged patent issues asserted by Allergan in this case are not infringed upon by Revance or our supply source partner Ajinomoto or are invalid," Revance said in a statement. "We are confident in the strength of our intellectual property and have done and will vigorously defend these allegations."
The lawsuit is one of several Allergan has filed against companies threatening to cut in on its aesthetics and therapeutics applications for Botox. Revance said lawsuits are "a frequent tactic" Allergan uses to "distract their competitors."
"If anything, we believe it speaks to Allergan's concern of how impactful our differentiated product will be in the market once approved," Revance said.
https://www.bizjournals.com/sanfrancisco/news/2021/10/04/botox-allergan-revance-daxi-frown-lines-ajinomoto.html?ana=TRUEANTHEMTWT_FR&csrc=6398&taid=615bf7fd76ce460001396e2b&utm_campaign=trueAnthem%3A+Trending+Content&utm_medium=trueAnthem&utm_source=twitter
B. Fosun concludes patient enrollment for Ph 3
https://twitter.com/medtechmd/status/1445013357044453378/photo/1
FWIW - a telling sign??
Two days ago there were 2. Now there are 9. Daxi's approval imminent? Who the hell knows! LOL
Commercial, Sales
Account Executive
Nashville, TN
Prestige Aesthetic Associate - Mid Atlantic
Remote
Prestige Aesthetic Associate - MidWest, Remote
United States
Prestige Aesthetic Associate - Northeast, Remote
United States
Prestige Aesthetic Associate - Southeast, Remote
United States
Prestige Aesthetic Associate - West, Remote
United States
Prestige Aesthetic Consultant (Memphis/Arkansas)
Little Rock, AR, Memphis, TN
Prestige Aesthetic Consultant - Mississippi
Jackson, Mississippi
Prestige Aesthetic Consultant - Orange County, CA
Orange County, CA
https://www.revance.com/careers/job-listings/
DaxibotulinumtoxinA for Injection Promising in the Treatment of Cervical Dystonia - September 24, 2021
The following article is part of conference coverage from the International Congress of Parkinson’s Disease and Movement Disorders (MDS) Virtual Annual Meeting.
DaxibotulinumtoxinA for Injection (DAXI) 125U and 250U, a novel botulinum toxin type A product with a proprietary peptide excipient, has shown to be safe and efficacious in reducing signs and symptoms associated with cervical dystonia in adults, according to study results presented at the International Congress of Parkinson’s Disease and Movement Disorders (MDS) Virtual Congress 2021, held from September 17 to 22, 2021.
[Further reading; we are knowledgeable with these results.]
https://www.neurologyadvisor.com/conference-highlights/mds-2021/daxibotulinumtoxina-for-injection-promising-in-the-treatment-of-cervical-dystonia/
General Counsel sells small amount of shares (734) -
https://ir.collegiumpharma.com/static-files/70d4a3b0-5d35-4b2e-a045-866dd489bd97
COLL vs. ZTS: Which Stock Should Value Investors Buy Now?
Zacks Equity Research
Mon, September 20, 2021, 11:40 AM
ZTS
+0.14%
COLL
-1.01%
Investors interested in Medical - Drugs stocks are likely familiar with Collegium Pharmaceutical (COLL) and Zoetis (ZTS). But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.
The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The Zacks Rank is a proven strategy that targets companies with positive earnings estimate revision trends, while our Style Scores work to grade companies based on specific traits.
Collegium Pharmaceutical and Zoetis are sporting Zacks Ranks of #1 (Strong Buy) and #3 (Hold), respectively, right now. The Zacks Rank favors stocks that have recently seen positive revisions to their earnings estimates, so investors should rest assured that COLL has an improving earnings outlook. However, value investors will care about much more than just this.
Value investors also try to analyze a wide range of traditional figures and metrics to help determine whether a company is undervalued at its current share price levels.
Our Value category grades stocks based on a number of key metrics, including the tried-and-true P/E ratio, the P/S ratio, earnings yield, and cash flow per share, as well as a variety of other fundamentals that value investors frequently use.
COLL currently has a forward P/E ratio of 5.31, while ZTS has a forward P/E of 43.84. We also note that COLL has a PEG ratio of 0.27. This popular figure is similar to the widely-used P/E ratio, but the PEG ratio also considers a company's expected EPS growth rate. ZTS currently has a PEG ratio of 3.17.
Another notable valuation metric for COLL is its P/B ratio of 2.76. The P/B ratio pits a stock's market value against its book value, which is defined as total assets minus total liabilities. For comparison, ZTS has a P/B of 21.62.
Based on these metrics and many more, COLL holds a Value grade of A, while ZTS has a Value grade of C.
COLL stands above ZTS thanks to its solid earnings outlook, and based on these valuation figures, we also feel that COLL is the superior value option right now.
https://finance.yahoo.com/news/coll-vs-zts-stock-value-154003011.html
Botulinum Toxin and the Treatment of Primary Disorders of Mood and Affect
They have a patent granted on this dated 2019-10-15
https://patents.justia.com/assignee/revance-therapeutics-inc
Now comes the expanded, updated version dated 2021-8-19
Excerpts:
The present invention relates to the treatment of primary disorders of mood and affect with a neurotoxin, including depressive, anxiety and sleep disorders as well as other CNS disorders.
Depression is one of the most prevalent and pervasive forms of mental illness that affects individuals across age and gender lines. The lifetime risk of major depression is about 12% in men and about 25% in women, generally...
The rate of relapse for patients with major depression is about 40% over a two-year period after a first episode. The occurrence of relapse increases to about 75% within a five year period after the diagnosis of a second episode of major depression.
In view of the sometimes severe adverse side effects and marginal efficacy of numerous antidepressant therapies, there is a great need for improved pharmaceuticals that effectively treat depressive disorders and sleep disorders without producing the side effects associated with treatments of depression and/or sleep disorders. The present invention provides compositions comprising botulinum toxin neurotoxin for the treatment of depressive and/or sleep disorders as well as other CNS disorders.
The present inventors have surprisingly and unexpectedly discovered criteria for the selection of subjects for the treatment of pain syndromes with botulinum toxin. The present invention provides methods for identifying subjects with an increased responsiveness to the treatment of pain with botulinum toxin. Specifically, the inventors have discovered that atopic disease is associated with various pain syndromes, and the presence of atopic disease and relief of pain by tactile stimulation, geste antagoniste phenomenon, seem to have predictive value in forecasting pain response to botulinum toxin.
The present invention provides methods of selecting patients suffering from various pain syndromes, including, but not limited to, myofascial pain, muscle tension headache, and chronic post operative wound syndromes, based on retrospective and prospective analysis in the application of botulinum toxin for the treatment of pain syndromes involving the head and neck.
Migraines, sleep disorders, anxiety disorders - all stated with beneficial results - further reading & analysis --
https://worldwide.espacenet.com/patent/search/family/037618561/publication/US2021252116A1?q=revance%20pharmaceuticals
Revance to Showcase Data from Phase 3 ASPEN-1 Clinical Trial Evaluating Efficacy, Duration of Effect and Safety of DaxibotulinumtoxinA for Injection for Cervical Dystonia at International Parkinson and Movement Disorder Society Virtual Congress 2021
"Data from the ASPEN-1 clinical trial continues to highlight DaxibotulinumtoxinA for Injection’s long duration of effect and encouraging safety profile for the treatment of cervical dystonia, reinforcing the drug product’s differentiated performance profile,” said Roman Rubio, Senior Vice President of Clinical Development at Revance. "We look forward to filing a Supplemental Biologics License Application, which may bring us one step closer to helping patients with this debilitating condition achieve long-lasting symptom relief."
https://investors.revance.com/news-releases/news-release-details/revance-showcase-data-phase-3-aspen-1-clinical-trial-evaluating
Top Pharmaceutical Stocks for Q4 2021
Best Value Pharmaceutical Stocks
These are the pharmaceutical stocks with the lowest 12-month trailing price-to-earnings (P/E) ratio. Because profits can be returned to shareholders in the form of dividends and buybacks, a low P/E ratio shows you’re paying less for each dollar of profit generated.
Collegium Pharmaceutical Inc.: Collegium Pharmaceutical is a pharmaceutical company specializing in pain management. It develops medications to treat acute and chronic pain. The company announced in mid-August that its board of directors authorized the repurchase of up to $100 million of the company's common stock. The timing and amount of share repurchases will be determined by management.
https://finance.yahoo.com/m/844e8960-46d3-33bd-9ae1-3dea2d091a69/top-pharmaceutical-stocks-for.html
Top Pharmaceutical Stocks for Q4 2021
Best Value Pharmaceutical Stocks
These are the pharmaceutical stocks with the lowest 12-month trailing price-to-earnings (P/E) ratio. Because profits can be returned to shareholders in the form of dividends and buybacks, a low P/E ratio shows you’re paying less for each dollar of profit generated.
Collegium Pharmaceutical Inc.: Collegium Pharmaceutical is a pharmaceutical company specializing in pain management. It develops medications to treat acute and chronic pain. The company announced in mid-August that its board of directors authorized the repurchase of up to $100 million of the company's common stock. The timing and amount of share repurchases will be determined by management.
https://finance.yahoo.com/m/844e8960-46d3-33bd-9ae1-3dea2d091a69/top-pharmaceutical-stocks-for.html
Revance Presents Data on the RHA® Collection of Dermal Fillers at the 2021 Virtual Skin of Color Update Meeting
September 10, 2021
** ePoster presentation highlights findings from a new post-hoc analysis evaluating efficacy and safety of the RHA® Collection -
** Supports Revance’s commitment to ensuring safety and efficacy of aesthetic product portfolio among diverse patient populations -
NASHVILLE, Tenn.--(BUSINESS WIRE)--Sep. 10, 2021-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that its data will be featured during the 2021 Virtual Skin of Color Update meeting, taking place September 10-12, 2021. The presentation highlights findings from a new post-hoc subgroup analysis evaluating the effectiveness and safety of the RHA® Collection of dermal fillers for the correction of moderate-to-severe nasolabial folds (NLFs) in patients with darker skin color.
“The RHA® Collection is the latest advancement in hyaluronic acid filler technology and we’re looking forward to sharing new data at the 2021 Virtual Skin of Color Update,” said Roman Rubio, Senior Vice President of Clinical Development at Revance. “The data presented highlights the safety and effectiveness of the RHA® Collection in treating moderate-to-severe nasolabial folds in an increasingly prominent patient population that is often underrepresented in clinical studies within aesthetic medicine. The study supports the innovation of Revance’s growing aesthetics portfolio while underscoring our commitment to proper treatment for diverse ethnicities and medical education for various skin types.”
The ePoster presentation will be available on-demand online via the Skin of Color Update website at skinofcolorupdate.com.
ePoster Presentation:
Title: Effectiveness and safety of Resilient Hyaluronic Acid (RHA®) dermal fillers for the correction of moderate-to-severe nasolabial folds in subjects with darker skin color: post-hoc subgroup analyses of US pivotal clinical data
Authors and Affiliations: Jay Mashburn, Kristie Kooken, Yan Liu, Revance Therapeutics, Inc., Nashville, TN
https://investors.revance.com/news-releases/news-release-details/revance-presents-data-rhar-collection-dermal-fillers-2021
Collegium Announces $100 Million Share Repurchase Program - COLL
(This is my partner with RVNC . Did not post this earlier.)
“Collegium is in a phase of growth and value creation, and this share repurchase program reflects our confidence in the underlying strength of our differentiated pain portfolio,” said Joe Ciaffoni, President and Chief Executive Officer of Collegium. “We are committed to maintaining a disciplined approach to capital allocation and we believe that our strong financial position gives us the flexibility to return cash to shareholders, execute on our business strategy and invest in our long-term growth.”
https://finance.yahoo.com/news/collegium-announces-100-million-share-120000826.html
Revance Announces Publication of Results on Static Glabellar Lines With Repeated Treatment of DaxibotulinumtoxinA for Injection From the SAKURA Clinical Program in Dermatologic Surgery
Fantastic news!!! Read
https://investors.revance.com/news-releases/news-release-details/revance-announces-publication-results-static-glabellar-lines
Jbog - Congrats - you are now an official recipient of the Craig Wheeler (MNTA) Fortune cookie, 20/20 medal.